# Study of VESIcare® In Overactive Bladder (OAB) Subjects to Evaluate Symptom Bother and Health Related Quality of Life

> **NCT00573508** · PHASE4 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 768 (actual)

## Conditions studied

- Urinary Bladder, Overactive

## Interventions

- **DRUG:** Placebo
- **DRUG:** Solifenacin Succinate

## Key facts

- **NCT ID:** NCT00573508
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-08
- **Primary completion:** 2008-07
- **Final completion:** 2008-07
- **Target enrollment:** 768 (ACTUAL)
- **Last updated:** 2010-10-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00573508

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00573508, "Study of VESIcare® In Overactive Bladder (OAB) Subjects to Evaluate Symptom Bother and Health Related Quality of Life". Retrieved via AI Analytics 2026-09-08 from https://api.ai-analytics.org/clinical/NCT00573508. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*